Tech Company Financing Transactions
DeepCure Funding Round
On 11/9/2021, DeepCure raised $40 million in Series A investment from Morningside Group, Benon and Sapir Venture Partners.
Transaction Overview
Company Name
Announced On
11/9/2021
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Proceeds Purpose
The proceeds from the Series A financing will be used to expand DeepCure's pipeline with five additional oncology programs and develop an automated robotic wet lab to fulfill its vision of developing drugs that are fully designed, synthesized, and tested by AI.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 City Hall Plaza
Boston, MA 02108
USA
Boston, MA 02108
USA
Phone
Undisclosed
Website
Email Address
Overview
DeepCure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. Our founding team includes some of the industry's preeminent drug-discovery scientists and technologists. Our vision is to use AI-driven discovery to create better molecules and faster cures for every disease-relevant protein target.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kfir Schreiber
Chief Scientific Officer
Joseph Jacobson
Chief Technical Officer
Thrasyvoulos Karydis
Browse more venture capital transactions:
Prev: 11/9/2021: Beacon Biosignals venture capital transaction
Next: 11/9/2021: Magnus Technologies venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs